20 November 2020AmericasSarah Morgan

Fed Circuit affirms GSK $107m patent loss

The US Court of Appeals for the Federal Circuit rejected GlaxoSmithKline’s (GSK) challenge of a $107 million verdict which found the drugmaker had infringed a dry-powder inhaler patent.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic

25 February 2021 A panel of the US Court of Appeals for the Federal Circuit has considered for a second time the $235 million award to GlaxoSmithKline after Teva Pharmaceuticals was found to have infringed its Coreg heart drug.

Americas

GSK, Amgen want SCOTUS to protect genus claims

18 November 2020 Patent law experts and pharmaceutical companies have lent their support to Merck Sharp & Dohme in its effort to confirm the patent-eligibility of genus claims at the US Supreme Court.

Big Pharma

Vectura wins additional $10m patent damages against GSK

16 September 2019 A district court has upped Vectura’s award of $89.7 million in damages by $10m, after a jury trial earlier this year found that GlaxoSmithKline has willfully infringed one of its patents.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Fed Circuit affirms GSK $107m patent loss

More on this story

Editor's picks

Editor's picks

More features